Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 8, 2010, Pages 901-910

  Hershcovici, T ^a   Leshno, M ^b   Goldin, E ^a   Shamir, R ^b,c   Israeli, E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CELIAC DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GLUTEN FREE DIET; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

ADULT; CELIAC DISEASE; COST-BENEFIT ANALYSIS; DELAYED DIAGNOSIS; DIET, GLUTEN-FREE; FEMALE; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 77949688475     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04242.x     Document Type: Article

References (66)

1. Green PH, Cellier C. Celiac disease. N Engl J Med 2007 357 : 1731 1743.
2. Schuppan D, Hahn EG. Biomedicine. Gluten and the gut-lessons for immune regulation. Science 2002 297 : 2218 2220.
3. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009 137 : 88 93.
4. Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 2001 358 : 356 361.
5. van Heel DA, West J. Recent advances in coeliac disease. Gut 2006 55 : 1037 1046.
6. Collin P. Should adults be screened for celiac disease? What are the benefits and harms of screening? Gastroenterology 2005 4 (Suppl 1 S104 8.
7. James SP. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005 128 (4 Suppl 1 S1 9.
8. Fasano A. European and North American populations should be screened for coeliac disease. Gut 2003 52 : 168 169.
9. Kumar PJ. European and North American populations should be screened for coeliac disease. Gut 2003 52 : 170 171.
10. Spiegel BM, Targownik LE, Kanwal F, et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology 2004 127 : 403 411.
11. Israeli E, Hershcovici T, Roach Z, Grotto I, Goldin E. Prevalence of celiac disease in the adult population in Israel. Gastroenterology 2008 134 (4 Supplement1 A 364.
12. Maki M, Mustalahti K, Kokkonen J, et al. Prevalence of Celiac disease among children in Finland. N Engl J Med 2003 348 : 2517 2524.
13. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003 163 : 286 292.
14. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007 26 : 1217 1225.
15. Olsson C, Hernell O, Hornell A, Lonnberg G, Ivarsson A. Difference in celiac disease risk between Swedish birth cohorts suggests an opportunity for primary prevention. Pediatrics 2008 122 : 528 534.
16. Cottone M, Termini A, Oliva L, et al. Mortality and causes of death in celiac disease in a Mediterranean area. Dig Dis Sci 1999 44 : 2538 2541.
17. West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004 329 : 716 719.
18. Shamir R, Hernell O, Leshno M. Cost-effectiveness analysis of screening for celiac disease in the adult population. Med Decis Making 2006 26 : 282 293.
19. Hogberg L, Grodzinsky E, Stenhammar L. Better dietary compliance in patients with coeliac disease diagnosed in early childhood. Scand J Gastroenterol 2003 38 : 751 754.
20. Baker PG, Barry RE, Read AE. Detection of continuing gluten ingestion in treated coeliac patients. Br Med J 1975 1 : 486 488.
21. Viljamaa M, Collin P, Huhtala H, Sievanen H, Maki M, Kaukinen K. Is coeliac disease screening in risk groups justified? A fourteen-year follow-up with special focus on compliance and quality of life Aliment Pharmacol Ther 2005 22 : 317 324.
22. Fabiani E, Taccari LM, Ratsch IM, Di Giuseppe S, Coppa GV, Catassi C. Compliance with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year follow-up study. J Pediatr 2000 136 : 841 843.
23. Leffler DA, Edwards George JB, Dennis M, Cook EF, Schuppan D, Kelly CP. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther 2007 26 : 1227 1235.
24. Hall NJ, Rubin G, Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009 30 : 315 330.
25. Whitaker JK, West J, Holmes GK, Logan RF. Patient perceptions of the burden of coeliac disease and its treatment in the UK. Aliment Pharmacol Ther 2009 29 : 1131 1136.
26. Hallert C, Granno C, Grant C, et al. Quality of life of adult coeliac patients treated for 10 years. Scand J Gastroenterol 1998 33 : 933 938.
27. Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE. Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997 17 : 1 9.
28. Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001 96 : 126 131.
29. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006 131 : 1981 2002.
30. Lankisch PG, Martinez Schramm A, Petersen F, Droge M, Lehnick D, Lembcke B. Diagnostic intervals for recognizing celiac disease. Z Gastroenterol 1996 34 : 473 477.
31. Dickey W, McConnell JB. How many hospital visits does it take before celiac sprue is diagnosed? J Clin Gastroenterol 1996 23 : 21 3.
32. Schramm AM, Lankisch PG. Long delay before celiac disease is recognized. J Clin Gastroenterol 1997 25 : 404 405.
33. Sanders DS, Hurlstone DP, Stokes RO, et al. Changing face of adult coeliac disease: experience of a single university hospital in South Yorkshire. Postgrad Med J 2002 78 : 31 3.
34. Hin H, Bird G, Fisher P, Mahy N, Jewell D. Coeliac disease in primary care: case finding study. BMJ 1999 318 : 164 167.
35. Cranney A, Zarkadas M, Graham ID, Switzer C. The Canadian celiac health survey - the Ottawa chapter pilot. BMC Gastroenterol 2003 3 : 8.
36. Zipser RD, Patel S, Yahya KZ, Baisch DW, Monarch E. Presentations of adult celiac disease in a nationwide patient support group. Dig Dis Sci 2003 48 : 761 764.
37. Cranney A, Zarkadas M, Graham ID, et al. The Canadian Celiac Health Survey. Dig Dis Sci 2007 52 : 1087 1095.
38. Rashtak S, Ettore MW, Homburger HA, Murray JA. Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease. Clin Gastroenterol Hepatol 2008 6 : 426 432. quiz 370.
39. Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010 31 : 73 81.
40. Cataldo F, Marino V, Bottaro G, Greco P, Ventura A. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997 131 : 306 308.
41. Kumar V, Jarzabek-Chorzelska M, Sulej J, Karnewska K, Farrell T, Jablonska S. Celiac disease and immunoglobulin a deficiency: how effective are the serological methods of diagnosis? Clin Diagn Lab Immunol 2002 9 : 1295 1300.
42. Cataldo F, Lio D, Marino V, Picarelli A, Ventura A, Corazza GR. IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Working Groups on Celiac Disease of SIGEP and Club del Tenue. Gut 2000 47 : 366 369.
43. Mein SM, Ladabaum U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004 19 : 1199 1210.
44. Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004 126 : 1721 1732.
45. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000 119 : 654 660.
46. Whitehead WE, Burnett CK, Cook EW III., Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996 41 : 2248 2253.
47. Ando K, Morita S, Higashi T, et al. Health-related quality of life among Japanese women with iron-deficiency anemia. Qual Life Res 2006 15 : 1559 1563.
48. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Inter Med 2003 138 : 176 186.
49. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001 96 : 3122 3129.
50. Csizmadia CG, Mearin ML, Oren A, et al. Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr 2000 137 : 756 761.
51. Stern M. Current therapy. In : Fasano A, Troncone R, Branski D, eds. Frontiers in Celiac Disease. Pediatric and Adolescent Medicine. Basel, New York : Karger, 2008 114 122.
52. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 146 : 473 481.
53. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 2004 13 : 437 452.
54. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009 302 : 1437 1443.
55. Alexander GC, Stafford RS. Does comparative effectiveness have a comparative edge? JAMA 2009 301 : 2488 2490.
56. Wilensky GR. Cost-effectiveness information: yes, it's important, but keep it separate, please! Ann Inter Med 2008 148 : 967 968.
57. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002 13 : 768 776.
58. Thomason K, West J, Logan RF, Coupland C, Holmes GK. Fracture experience of patients with coeliac disease: a population based survey. Gut 2003 52 : 518 522.
59. West J, Logan RF, Card TR, Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 2003 125 : 429 436.
60. Vasquez H, Mazure R, Gonzalez D, et al. Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol 2000 95 : 183 189.
61. Moreno ML, Vazquez H, Mazure R, et al. Stratification of bone fracture risk in patients with celiac disease. Clin Gastroenterol Hepatol 2004 2 : 127 134.
62. Ludvigsson JF, Michaelsson K, Ekbom A, Montgomery SM. Coeliac disease and the risk of fractures - a general population-based cohort study. Aliment Pharmacol Ther 2007 25 : 273 285.
63. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002 156 : 1 10.
64. Fickling WE, McFarlane XA, Bhalla AK, Robertson DA. The clinical impact of metabolic bone disease in coeliac disease. Postgrad Med J 2001 77 : 33 6.
65. Lohi S, Maki M, Montonen J, et al. Malignancies in cases with screening-identified evidence of coeliac disease: a long-term population-based cohort study. Gut 2009 58 : 618 619.
66. Solaymani-Dodaran M, West J, Logan RF. Long-term mortality in people with celiac disease diagnosed in childhood compared with adulthood: a population-based cohort study. Am J Gastroenterol 2007 102 : 864 870.